New cell therapy takes on Hard-to-Treat stomach cancer
NCT ID NCT07333820
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment called AB-201 for advanced HER2-positive stomach or gastroesophageal junction cancer. AB-201 uses specially engineered natural killer cells to target and kill cancer cells. The study will enroll 18 adults whose cancer has not responded to or cannot tolerate standard treatments, focusing first on safety and then on whether the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AB-201 (a HER2-targeted cell therapy made from natural killer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced HER2-positive stomach cancer who have run out of standard options.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, so it is primarily testing safety. The treatment may not shrink tumors, and side effects could be serious. Success is far from guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF STOMACH, UNSPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
minkyu Jung
Seoul, 03722, South Korea